A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of p2x3 receptor antagonist sivopixant for refractory or unexplained chronic cough

Lorcan McGarvey, Jaclyn A Smith, Alyn Morice, Surinder S Birring, Kian Fan Chung, Peter V Dicpinigaitis, Akio Niimi, Michael S Benninger, Mandel Sher, Yuko Matsunaga, Sayaka Miyazaki, Mitsuaki Machida, Hiroyuki Ishihara, Adnan Mahmood, Juan-Carlos Gomez

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
50 Downloads (Pure)

Abstract

Introduction: To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC).Methods: In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, patients received sivopixant 50, 150, or 300 mg or placebo once daily for 4 weeks. The primary endpoint was a change from baseline in 24-h cough frequency (coughs/h) with sivopixant vs placebo. Results: Overall, 390/406 randomized patients completed the study. Placebo-adjusted changes in hourly cough count over 24 h were 13.17% (P = 0.3532), - 1.77% (P = 0.8935), and - 12.47% (P = 0.3241) and in cough severity (visual analog scale) were 1.75 mm (P = 0.5854), - 1.21 mm (P = 0.7056), and - 6.55 mm (P = 0.0433) with sivopixant 50, 150, and 300 mg, respectively. Placebo-adjusted changes from baseline in Leicester Cough Questionnaire total scores were - 0.37 (P = 0.4207), - 0.07 (P = 0.8806), and 0.69 (P = 0.1473) with sivopixant 50, 150, and 300 mg, respectively. Additionally, 61.3%, 78.3%, 86.8%, and 71.4% of patients receiving sivopixant 50, 150, and 300 mg and placebo, respectively, reported any improvements in Patient Global Impression of Change. The incidence of treatment-emergent adverse events (TEAEs) was 25.7%, 32.0%, 49.0%, and 20.6% in sivopixant 50, 150, and 300 mg and placebo groups, respectively; all TEAEs in the sivopixant group were mild-to-moderate. Conclusion: Sivopixant did not demonstrate a statistically significant difference vs placebo in change from baseline in 24-h cough frequency. The dose of 300 mg has potential for RCC/UCC, showing the greatest improvements in cough frequency and patient-reported outcomes and dose-related mild to moderate reversible taste disturbance, although further trials are needed. Clinical trial registrationClinicalTrials.gov identifier NCT04110054; registered September 26, 2019.
Original languageEnglish
Number of pages11
JournalLung
Early online date13 Dec 2022
DOIs
Publication statusEarly online date - 13 Dec 2022

Keywords

  • Chronic Cough
  • Cough Frequency
  • P2x3 Receptor Antagonist
  • Phase 2B Trial
  • Sivopixant

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of p2x3 receptor antagonist sivopixant for refractory or unexplained chronic cough'. Together they form a unique fingerprint.

Cite this